Results 231 to 240 of about 129,119 (300)

Phenotypic Clues in Infantile‐Onset Parkinsonism‐Dystonia‐2: A Treatable Neurotransmitter Disorder

Movement Disorders Clinical Practice, EarlyView.
Sangeetha Yoganathan, Haya S. AlFaris, Lindsey Vogt, Michele Eid, Anika Menetrey, Sayoni Roy Chowdhury, Dawn Codeiro, Pradeep Krishnan, Liali Aljouda, Emily W.Y. Tam, Carolina Gorodetsky   +10 more
wiley   +1 more source

Phenotypic Exploration in Patients with Heterozygous Variant in AFG3L2 Gene: A Case‐Series and Literature Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Variants in AFG3‐Like Matrix AAA Peptidase, Subunit 2 (AFG3L2) gene are associated with diverse clinical phenotypes. Here, we describe phenotypic findings of two unrelated children with de novo heterozygous variant and one family with inherited heterozygous variant in AFG3L2 gene.
Sangeetha Yoganathan, Laura Tochen, Jacky Ganguly, Sayoni Roy Chowdhury, Haya S AlFaris, Vivek Pai, Andrea LeBlanc‐Millar, Sara Breitbart, Hrishikesh Kumar, Manohar Shroff, Arun Reginald, Grace Yoon, Alfonso Fasano, George M Ibrahim, Carolina Gorodetsky   +14 more
wiley   +1 more source

Author Reply: Isolated Aripiprazole-Associated Cervical Tremor-Like Movement and Possible Dystonic Features. [PDF]

J Gen Fam Med
Sada RM, Minoda SS.
europepmc   +1 more source

Continuous Apomorphine Infusion in Multiple System Atrophy Real‐World Insights From a French Nationwide Retrospective Cohort

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Continuous subcutaneous apomorphine infusion (CSAI) is effective in Parkinson's disease but has not been evaluated in multiple system atrophy (MSA). Objective To assess the 6‐month efficacy and tolerability of CSAI in MSA patients. Methods French multicenter retrospective registry‐based analysis of CSAI use in MSA.
Simon Lamy, Frederique Leh, Alexandra Foubert‐Samier, Soizic Leguy Bonnet, Guillaume Baille, Margherita Fabbri, Margaux Dunoyer, Lise Mantisi, Caroline Giordana, Anaïs El Ouartassi, Olivier Rascol, Wassilios G. Meissner, David Bendetowicz, Marie Vanel, David Grabli, Fabienne Ory‐Magne, Sophie Drapier   +16 more
wiley   +1 more source

Prevalence of Diagnosed Essential Tremor Using Electronic Healthcare Records: A Population-Based Study in Northeast-Central Pennsylvania. [PDF]

Tremor Other Hyperkinet Mov (N Y)
Kratovil D, Jung SY, Stoica S, Roy M, Stanciu AC, Sandulescu MC.   +5 more
europepmc   +1 more source

Framework for Approaching Patients with Suboptimal Deep Brain Stimulation Therapy Response despite Stimulation Optimization

Movement Disorders Clinical Practice, EarlyView.
Pratik Talati, Meredith Spindler, Casey H. Halpern   +2 more
wiley   +1 more source

Real‐World Patterns of Botulinum Toxin Treatment in Hyperkinetic Movement Disorders: A 9‐Year Nationwide Analysis in France

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Hyperkinetic movement disorders, including dystonia, tremor, and myoclonus, are disabling conditions often managed with botulinum toxin type A (BoNT‐A). Real‐world evidence on treatment patterns remains limited. Objective This nationwide, population‐based study aimed to evaluate trends in BoNT‐A use in France between 2015 and 2023 ...
Marion Simonetta‐Moreau, Pierre Karam, Anne Forestier, Bertrand Degos   +3 more
wiley   +1 more source

Feasibility Pilot of the LaceUp Compression-Weight Sleeve for Essential Tremor. [PDF]

Bioengineering (Basel)
Napoli A, Gravante H, Hamilton T, Gerhardt N, Serruya MD.   +4 more
europepmc   +1 more source

Efficacy of IncobotulinumtoxinA (BoNT-A) Injections in Upper Limb Task-Specific and Position-Dependent Tremors. [PDF]

Mov Disord Clin Pract
Boyd EK, Jiang S, Shi RB, Rizek P.
europepmc   +1 more source

A Fully Magnetic Resonance Imaging-Compatible, Nonelectrical System for Near-Real-Time Tremor Monitoring during Magnetic Resonance-Guided Focused Ultrasound.

Stereotact Funct Neurosurg
Lavalley A, Lorton O, Constanthin P, Fleury V, Momjian S.   +4 more
europepmc   +1 more source